Kliniek Development: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Kliniek Development
Largest movements
- Stocks and contracts +€1.3m
up €1.3m (+78.9%), from €1.6m to €2.9m
- Deferred charges and accrued income +€127,532
up €127,532 (+319.6%), from €39,898 to €167,430
- Receivables within one year +€81,158
up €81,158 (+80.3%), from €101,110 to €182,268
of which Other amounts receivable: +€64,564
- Trade debts +€877,132
up €877,132 (+776.9%), from €112,902 to €990,034
- Debts after one year +€723,582
up €723,582 (+40.4%), from €1.8m to €2.5m
- Profit (loss) carried forward -€91,632
down €91,632 (-84.5%), from -€108,414 to -€200,046
- Gross operating margin -€77,602
down €77,602 (-1828.6%), from -€4,244 to -€81,846
- Financial charges +€8,090
up €8,090 (+1461.9%), from €553 to €8,644
- Other operating charges +€1,002
up €1,002 (+713.2%), from €141 to €1,143
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,802,530 | €3,311,669 | +€1.5m | +83.7% |
| Current assets | 29/58 | €1,802,530 | €3,311,669 | +€1.5m | +83.7% |
| Stocks and contracts in progress | 3 | €1,646,211 | €2,944,525 | +€1.3m | +78.9% |
| Stocks | 30/36 | €1,646,211 | €2,944,525 | +€1.3m | +78.9% |
| Amounts receivable within one year | 40/41 | €101,110 | €182,268 | +€81,158 | +80.3% |
| Trade receivables | 40 | €86,921 | €103,514 | +€16,593 | +19.1% |
| Other amounts receivable | 41 | €14,189 | €78,754 | +€64,564 | +455.0% |
| Cash at bank and in hand | 54/58 | €15,312 | €17,447 | +€2,135 | +13.9% |
| Deferred charges and accrued income | 490/1 | €39,898 | €167,430 | +€127,532 | +319.6% |
| Total equity and liabilities | 10/49 | €1,802,530 | €3,311,669 | +€1.5m | +83.7% |
| Equity | 10/15 | -€103,414 | -€195,046 | -€91,632 | -88.6% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€108,414 | -€200,046 | -€91,632 | -84.5% |
| Amounts payable | 17/49 | €1,905,944 | €3,506,715 | +€1.6m | +84.0% |
| Amounts payable after more than one year | 17 | €1,792,979 | €2,516,561 | +€723,582 | +40.4% |
| Financial debts | 170/4 | €1,792,979 | €2,516,561 | +€723,582 | +40.4% |
| Amounts payable within one year | 42/48 | €112,902 | €990,114 | +€877,212 | +777.0% |
| Trade debts | 44 | €112,902 | €990,034 | +€877,132 | +776.9% |
| Suppliers | 440/4 | €112,902 | €990,034 | +€877,132 | +776.9% |
| Advances received on contracts in progress | 46 | €0 | - | = | |
| Taxes, remuneration and social security | 45 | - | €80 | +€80 | |
| Taxes | 450/3 | - | €80 | +€80 | |
| Accrued charges and deferred income | 492/3 | €63 | €40 | -€23 | -36.0% |
| Other operating charges | 640/8 | €141 | €1,143 | +€1,002 | +713.2% |
| Gross operating margin | 9900 | -€4,244 | -€81,846 | -€77,602 | -1828.6% |
| Operating profit (loss) | 9901 | -€4,384 | -€82,988 | -€78,604 | -1792.8% |
| Financial charges | 65/66B | €553 | €8,644 | +€8,090 | +1461.9% |
| Recurring financial charges | 65 | €553 | €8,644 | +€8,090 | +1461.9% |
| Profit (loss) for the period before taxes | 9903 | -€4,938 | -€91,632 | -€86,694 | -1755.7% |
| Profit (loss) for the period | 9904 | -€4,938 | -€91,632 | -€86,694 | -1755.7% |
| Profit (loss) for the period to be appropriated | 9905 | -€4,938 | -€91,632 | -€86,694 | -1755.7% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.